secwatch.observer — SEC 8-K summary
======================================

Issuer:     AVENUE THERAPEUTICS, INC. (ATXI)
CIK:        0001644963
Form:       8-K
Filed at:   2024-11-14T23:59:59+00:00
Accession:  0001437749-24-035304
Event type: earnings
Sentiment:  negative
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Avenue Therapeutics Q3 2024 net loss $3.1M; cash $2.6M; AJ201 data expected year-end
--------------------------------------------------------------------------------

- Net loss of $3.1M ($1.92/share) vs net income of $0.5M in Q3 2023.
- Cash and equivalents $2.6M at Sep 30, 2024, down $2.3M from Q2 2024.
- R&D expenses $2.3M, up from $0.9M in prior year; G&A $0.8M down from $1.2M.
- Topline data from AJ201 Phase 1b/2a trial in SBMA expected around year-end 2024.
- IV Tramadol Phase 3 safety protocol finalized with FDA; study start subject to financing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1644963/000143774924035304/0001437749-24-035304-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1644963/000143774924035304/atxi20241114_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-24-035304

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer